These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35368605)

  • 1. Depression and the Effect of Sertraline on Inflammatory Biomarkers in Patients with Nondialysis CKD.
    Gregg LP; Carmody T; Le D; Bharadwaj N; Trivedi MH; Hedayati SS
    Kidney360; 2020 Jun; 1(6):436-446. PubMed ID: 35368605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial.
    Hedayati SS; Gregg LP; Carmody T; Jain N; Toups M; Rush AJ; Toto RD; Trivedi MH
    JAMA; 2017 Nov; 318(19):1876-1890. PubMed ID: 29101402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of platelet function with depression and its treatment with sertraline in patients with chronic kidney disease: analysis of a randomized trial.
    Jain N; Wan F; Kothari M; Adelodun A; Ware J; Sarode R; Hedayati SS
    BMC Nephrol; 2019 Oct; 20(1):395. PubMed ID: 31664940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs.
    Shelton RC; Pencina MJ; Barrentine LW; Ruiz JA; Fava M; Zajecka JM; Papakostas GI
    J Clin Psychiatry; 2015 Dec; 76(12):1635-41. PubMed ID: 26613389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST).
    Jain N; Trivedi MH; Rush AJ; Carmody T; Kurian B; Toto RD; Sarode R; Hedayati SS
    Contemp Clin Trials; 2013 Jan; 34(1):136-44. PubMed ID: 23085503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of inflammation-based stratification for add-on celecoxib or minocycline in major depressive disorder: Protocol of the INSTA-MD double-blind placebo-controlled randomised clinical trial.
    Wessa C; Janssens J; Coppens V; El Abdellati K; Vergaelen E; van den Ameele S; Baeken C; Zeeuws D; Milaneschi Y; Lamers F; Penninx B; Claes S; Morrens M; De Picker L
    Brain Behav Immun Health; 2024 Nov; 41():100871. PubMed ID: 39350954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic and psychological interventions for depression treatment in patients with kidney disease.
    Gregg LP; Hedayati SS
    Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):457-464. PubMed ID: 32701597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for Anti-inflammatory Effects of Adalimumab in Treatment of Patients With Major Depressive Disorder: A Pilot, Randomized, Controlled Trial.
    Abbasian F; Bagheri S; Moradi K; Keykhaei M; Etemadi A; Shalbafan M; Shariati B; Vaseghi S; Samsami FS; Akhondzadeh S
    Clin Neuropharmacol; 2022 Sep-Oct 01; 45(5):128-134. PubMed ID: 36093920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression.
    Bot M; Carney RM; Freedland KE; Rubin EH; Rich MW; Steinmeyer BC; Mann DL
    J Psychosom Res; 2011 Jul; 71(1):13-7. PubMed ID: 21665007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.
    Abbasi SH; Hosseini F; Modabbernia A; Ashrafi M; Akhondzadeh S
    J Affect Disord; 2012 Dec; 141(2-3):308-14. PubMed ID: 22516310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation-stratified augmentation of vortioxetine with celecoxib: Results from a double-blind, randomized, placebo-controlled trial in major depressive disorder.
    Kavakbasi E; Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert KO; Clark SR; Fourrier C; Baune BT
    J Neurochem; 2024 Sep; 168(9):1817-1825. PubMed ID: 37635396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: results of a randomized double-blind, placebo-controlled clinical trial.
    Taraz M; Khatami MR; Dashti-Khavidaki S; Akhonzadeh S; Noorbala AA; Ghaeli P; Taraz S
    Int Immunopharmacol; 2013 Nov; 17(3):917-23. PubMed ID: 24121064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation and Response to Sertraline Treatment in Patients With CKD and Major Depression.
    Gregg LP; Carmody T; Le D; Toto RD; Trivedi MH; Hedayati SS
    Am J Kidney Dis; 2020 Mar; 75(3):457-460. PubMed ID: 31866226
    [No Abstract]   [Full Text] [Related]  

  • 15. C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebo-controlled trial.
    Raison CL; Siu C; Pikalov A; Tocco M; Loebel A
    Brain Behav Immun; 2020 Feb; 84():269-274. PubMed ID: 31857217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation Markers and Major Depressive Disorder in Patients With Chronic Heart Failure: Results From the Sertraline Against Depression and Heart Disease in Chronic Heart Failure Study.
    Xiong GL; Prybol K; Boyle SH; Hall R; Streilein RD; Steffens DC; Krishnan R; Rogers JG; O'Connor CM; Jiang W;
    Psychosom Med; 2015 Sep; 77(7):808-15. PubMed ID: 26186432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design.
    Trivedi MH; McGrath PJ; Fava M; Parsey RV; Kurian BT; Phillips ML; Oquendo MA; Bruder G; Pizzagalli D; Toups M; Cooper C; Adams P; Weyandt S; Morris DW; Grannemann BD; Ogden RT; Buckner R; McInnis M; Kraemer HC; Petkova E; Carmody TJ; Weissman MM
    J Psychiatr Res; 2016 Jul; 78():11-23. PubMed ID: 27038550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obstructive sleep apnea/hypopnea syndrome and poor response to sertraline in patients with coronary heart disease.
    Roest AM; Carney RM; Stein PK; Freedland KE; Meyer H; Steinmeyer BC; de Jonge P; Rubin EH
    J Clin Psychiatry; 2012 Jan; 73(1):31-6. PubMed ID: 21903027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD.
    Nowak KL; Kakkar R; Devalaraja M; Lo L; Park W; Gobburu J; Kling D; Davidson M; Chonchol M
    Kidney360; 2021 Feb; 2(2):224-235. PubMed ID: 35373026
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.